218 related articles for article (PubMed ID: 33045723)
1. The Potential Epidemiological Impact of Coronavirus Disease 2019 (COVID-19) on the Human Immunodeficiency Virus (HIV) Epidemic and the Cost-effectiveness of Linked, Opt-out HIV Testing: A Modeling Study in 6 US Cities.
Zang X; Krebs E; Chen S; Piske M; Armstrong WS; Behrends CN; Del Rio C; Feaster DJ; Marshall BDL; Mehta SH; Mermin J; Metsch LR; Schackman BR; Strathdee SA; Nosyk B;
Clin Infect Dis; 2021 Jun; 72(11):e828-e834. PubMed ID: 33045723
[TBL] [Abstract][Full Text] [Related]
2. Clinical Outcomes, Costs, and Cost-effectiveness of Strategies for Adults Experiencing Sheltered Homelessness During the COVID-19 Pandemic.
Baggett TP; Scott JA; Le MH; Shebl FM; Panella C; Losina E; Flanagan C; Gaeta JM; Neilan A; Hyle EP; Mohareb A; Reddy KP; Siedner MJ; Harling G; Weinstein MC; Ciaranello A; Kazemian P; Freedberg KA
JAMA Netw Open; 2020 Dec; 3(12):e2028195. PubMed ID: 33351082
[TBL] [Abstract][Full Text] [Related]
3. Emergency Room "Opt-Out" HIV Testing Pre- and During COVID-19 Pandemic in a Large Community Health System.
Eckardt P; Niu J; Montalvo S
J Int Assoc Provid AIDS Care; 2021; 20():23259582211041260. PubMed ID: 34488480
[TBL] [Abstract][Full Text] [Related]
4. Concurrent Testing for COVID-19 and HIV Infection at 6 High-Volume Emergency Departments in a Priority Jurisdiction for Ending the HIV Epidemic in the United States.
McNulty MC; Stanford KA; Eller D; Sha BE; Purim-Shem-Tov Y; Kishen E; Glick N; Hunt B; Lin JY; Maheswaran A; Galvin S; Turelli R; Schmitt J; Pitrak D
J Acquir Immune Defic Syndr; 2023 Dec; 94(4):364-370. PubMed ID: 37884056
[TBL] [Abstract][Full Text] [Related]
5. Improving health equity and ending the HIV epidemic in the USA: a distributional cost-effectiveness analysis in six cities.
Quan AML; Mah C; Krebs E; Zang X; Chen S; Althoff K; Armstrong W; Behrends CN; Dombrowski JC; Enns E; Feaster DJ; Gebo KA; Goedel WC; Golden M; Marshall BDL; Mehta SH; Pandya A; Schackman BR; Strathdee SA; Sullivan P; Tookes H; Nosyk B;
Lancet HIV; 2021 Sep; 8(9):e581-e590. PubMed ID: 34370977
[TBL] [Abstract][Full Text] [Related]
6. Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: results from multiple mathematical models.
Jewell BL; Mudimu E; Stover J; Ten Brink D; Phillips AN; Smith JA; Martin-Hughes R; Teng Y; Glaubius R; Mahiane SG; Bansi-Matharu L; Taramusi I; Chagoma N; Morrison M; Doherty M; Marsh K; Bershteyn A; Hallett TB; Kelly SL;
Lancet HIV; 2020 Sep; 7(9):e629-e640. PubMed ID: 32771089
[TBL] [Abstract][Full Text] [Related]
7. Ending the HIV epidemic in the USA: an economic modelling study in six cities.
Nosyk B; Zang X; Krebs E; Enns B; Min JE; Behrends CN; Del Rio C; Dombrowski JC; Feaster DJ; Golden M; Marshall BDL; Mehta SH; Metsch LR; Pandya A; Schackman BR; Shoptaw S; Strathdee SA;
Lancet HIV; 2020 Jul; 7(7):e491-e503. PubMed ID: 32145760
[TBL] [Abstract][Full Text] [Related]
8. Epidemiological, Virological and Serological Features of Coronavirus Disease 2019 (COVID-19) Cases in People Living With Human Immunodeficiency Virus in Wuhan: A Population-based Cohort Study.
Huang J; Xie N; Hu X; Yan H; Ding J; Liu P; Ma H; Ruan L; Li G; He N; Wei S; Wang X
Clin Infect Dis; 2021 Oct; 73(7):e2086-e2094. PubMed ID: 32803216
[TBL] [Abstract][Full Text] [Related]
9. Prediction of the Transition From Subexponential to the Exponential Transmission of SARS-CoV-2 in Chennai, India: Epidemic Nowcasting.
Krishnamurthy K; Ambikapathy B; Kumar A; Britto L
JMIR Public Health Surveill; 2020 Sep; 6(3):e21152. PubMed ID: 32609621
[TBL] [Abstract][Full Text] [Related]
10. Clinical and Economic Effects of Widespread Rapid Testing to Decrease SARS-CoV-2 Transmission.
Paltiel AD; Zheng A; Sax PE
Ann Intern Med; 2021 Jun; 174(6):803-810. PubMed ID: 33683930
[TBL] [Abstract][Full Text] [Related]
11. Comparative cost-effectiveness of SARS-CoV-2 testing strategies in the USA: a modelling study.
Du Z; Pandey A; Bai Y; Fitzpatrick MC; Chinazzi M; Pastore Y Piontti A; Lachmann M; Vespignani A; Cowling BJ; Galvani AP; Meyers LA
Lancet Public Health; 2021 Mar; 6(3):e184-e191. PubMed ID: 33549196
[TBL] [Abstract][Full Text] [Related]
12. The impact of localized implementation: determining the cost-effectiveness of HIV prevention and care interventions across six United States cities.
Krebs E; Zang X; Enns B; Min JE; Behrends CN; Del Rio C; Dombrowski JC; Feaster DJ; Gebo KA; Golden M; Marshall BDL; Metsch LR; Schackman BR; Shoptaw S; Strathdee SA; Nosyk B;
AIDS; 2020 Mar; 34(3):447-458. PubMed ID: 31794521
[TBL] [Abstract][Full Text] [Related]
13. Modeling the epidemiological impact of the UNAIDS 2025 targets to end AIDS as a public health threat by 2030.
Stover J; Glaubius R; Teng Y; Kelly S; Brown T; Hallett TB; Revill P; Bärnighausen T; Phillips AN; Fontaine C; Frescura L; Izazola-Licea JA; Semini I; Godfrey-Faussett P; De Lay PR; Benzaken AS; Ghys PD
PLoS Med; 2021 Oct; 18(10):e1003831. PubMed ID: 34662333
[TBL] [Abstract][Full Text] [Related]
14. Household Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 From Adult Index Cases With and Without Human Immunodeficiency Virus in South Africa, 2020-2021: A Case-Ascertained, Prospective, Observational Household Transmission Study.
Kleynhans J; Walaza S; Martinson NA; Neti M; von Gottberg A; Bhiman JN; Toi D; Amoako DG; Buys A; Ndlangisa K; Wolter N; Genade L; Maloma L; Chewparsad J; Lebina L; de Gouveia L; Kotane R; Tempia S; Cohen C
Clin Infect Dis; 2023 Feb; 76(3):e71-e81. PubMed ID: 35925613
[TBL] [Abstract][Full Text] [Related]
15. Costs and consequences of the US Centers for Disease Control and Prevention's recommendations for opt-out HIV testing.
Holtgrave DR
PLoS Med; 2007 Jun; 4(6):e194. PubMed ID: 17564488
[TBL] [Abstract][Full Text] [Related]
16. HIV infection and risk, prevention, and testing behaviors among injecting drug users -- National HIV Behavioral Surveillance System, 20 U.S. cities, 2009.
Broz D; Wejnert C; Pham HT; DiNenno E; Heffelfinger JD; Cribbin M; Krishna N; Teshale EH; Paz-Bailey G;
MMWR Surveill Summ; 2014 Jul; 63(6):1-51. PubMed ID: 24990587
[TBL] [Abstract][Full Text] [Related]
17. Active testing of groups at increased risk of acquiring SARS-CoV-2 in Canada: costs and human resource needs.
Campbell JR; Uppal A; Oxlade O; Fregonese F; Bastos ML; Lan Z; Law S; Oh CE; Russell WA; Sulis G; Winters N; Yanes-Lane M; Brisson M; Laszlo S; Evans TG; Menzies D
CMAJ; 2020 Oct; 192(40):E1146-E1155. PubMed ID: 32907820
[TBL] [Abstract][Full Text] [Related]
18. Assessing the Potential Impact of Disruptions Due to COVID-19 on HIV Among Key and Lower-Risk Populations in the Largest Cities of Cameroon and Benin.
Silhol R; Geidelberg L; Mitchell KM; Mishra S; Dimitrov D; Bowring A; Béhanzin L; Guédou F; Diabaté S; Schwartz S; Billong SC; Njindam IM; Levitt D; Mukandavire C; Maheu-Giroux M; Rönn MM; Dalal S; Vickerman P; Baral S; Alary M; Boily MC
J Acquir Immune Defic Syndr; 2021 Jul; 87(3):899-911. PubMed ID: 33657058
[TBL] [Abstract][Full Text] [Related]
19. Contact Tracing for COVID-19: An Opportunity to Reduce Health Disparities and End the Human Immunodeficiency Virus/AIDS Epidemic in the United States.
Nosyk B; Armstrong WS; Del Rio C
Clin Infect Dis; 2020 Nov; 71(16):2259-2261. PubMed ID: 32339245
[TBL] [Abstract][Full Text] [Related]
20. Novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) co-infection with HIV: clinical case series analysis in North Central Nigeria.
Akyala AI; Iwu CJ
Pan Afr Med J; 2020; 37():47. PubMed ID: 33209174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
